casdatifan + volrustomig — Interim data
2H 2026
• 2H 2026: Data from the Phase 1b portion and a go-no-go decision on the Phase 3 portion of eVOLVE-RCC02.Source filing
RCUS biotech catalysts & pipeline
ARCUS BIOSCIENCES INC · Data as of 2026-10-25
Upcoming catalysts
quemliclustat — Clinical data readout
H1 2027
Results from this study are expected in the first half of 2027.Source filing
AB102 — Initial data
mid-2027
A proof-of-concept study evaluating AB102 as a potential oral therapy for patients with chronic spontaneous urticaria is expected in mid-2027.Source filing